Skip to main content Accessibility help
×
Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-26T21:15:47.596Z Has data issue: false hasContentIssue false

Chapter 40 - Diagnosis of Epithelial Ovarian, Fallopian Tubal and Peritoneal Surface Cancers

from Section 9 - Ovary and Fallopian Tubes

Published online by Cambridge University Press:  24 November 2021

Tahir Mahmood
Affiliation:
Victoria Hospital, Kirkcaldy
Charles Savona-Ventura
Affiliation:
University of Malta, Malta
Ioannis Messinis
Affiliation:
University of Thessaly, Greece
Sambit Mukhopadhyay
Affiliation:
Norfolk & Norwich University Hospital, UK
Get access

Summary

Epithelial ovarian cancers probably derive in the case of the serous histotype from the fimbrial end of the fallopian tube. There is no screening for this disease, which might impact on the overall mortality rate. Therefore, it is crucial to identify patients with higher risk by taking a thorough family history and performing genetic counselling and testing. Diagnostic methods used are tumour marker CA-125, transvaginal ultrasound and CT imaging; however, neither alone nor in combination will these methods detect the disease earlier, even if performed in regular controls. A fixed pelvic mass on bimanual examination is a typical feature for pelvic disease, while extended abdomen and ascites is pathognomonic for peritoneal disease. The prognosis has improved over the years due to more radical debulking in advanced stages and improved adjuvant therapies.

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2021

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kurman, RJ, Shih, IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 2008;27:151160.Google ScholarPubMed
Levanon, K, Crum, C, Drapkin, R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26:52845293.Google Scholar
Kurman, RJ, Shih, IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433443.CrossRefGoogle ScholarPubMed
Anglesio, MS, Papadopoulos, N, Ayhan, A, et al. Cancer-associated mutations in endometriosis without cancer. N Engl J Med 2017;376:18351848.CrossRefGoogle ScholarPubMed
Kvaskoff, M, Horne, AW, Missmer, SA. Informing women with endometriosis about ovarian cancer risk. Lancet 2017;390:24332434.Google Scholar
Bolton, KL, Chenevix-Trench, G, Goh, C, et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 2012;307:382390.CrossRefGoogle ScholarPubMed
Norquist, BM, Harrell, MI, Brady, MF, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2:482490.CrossRefGoogle ScholarPubMed
Finch, AP, Lubinski, J, Moller, P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014;32:15471553.CrossRefGoogle ScholarPubMed
Buys, SS, Partridge, E, Black, A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305:22952303.CrossRefGoogle ScholarPubMed
Jacobs, IJ, Menon, U, Ryan, A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 2016;387:945956.CrossRefGoogle ScholarPubMed
Kobayashi, H, Yamada, Y, Sado, T, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. Int J Gynecol Cancer 2008;18:414420.CrossRefGoogle ScholarPubMed
van Nagell, JR, Jr., Miller, RW, DeSimone, CP, et al. Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening. Obstet Gynecol 2011;118:12121221.CrossRefGoogle ScholarPubMed
van der Velde, NM, Mourits, MJ, Arts, HJ, et al. Time to stop ovarian cancer screening in BRCA1/2 mutation carriers? Int J Cancer 2009;124:919923.CrossRefGoogle ScholarPubMed
Goff, BA, Mandel, LS, Melancon, CH, Muntz, HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA 2004;291:27052712.CrossRefGoogle ScholarPubMed
Schnatz, PF, Guile, M, O’Sullivan, DM, Sorosky, JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006;107:701708.Google Scholar
Jacob, F, Meier, M, Caduff, R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol 2011;121:487491.CrossRefGoogle ScholarPubMed
Zaino, R, Whitney, C, Brady, MF, et al. Simultaneously detected endometrial and ovarian carcinomas: a prospective clinicopathologic study of 74 cases: a gynecologic oncology group study. Gynecol Oncol 2001;83:355362.Google Scholar
Jacobs, I, Oram, D, Fairbanks, J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990;97:922929.CrossRefGoogle ScholarPubMed
Chia, YN, Marsden, DE, Robertson, G, Hacker, NF. Triage of ovarian masses. Aust N Z J Obstet Gynaecol 2008;48:322328.Google Scholar
Manegold-Brauer, G, Buechel, J, Knipprath-Meszaros, A, et al. Improved detection rate of ovarian cancer using a 2-step triage model of the risk of malignancy index and expert sonography in an outpatient screening setting. Int J Gynecol Cancer 2016;26:10621069.CrossRefGoogle Scholar
Timmerman, D, Van Calster, B, Testa, A, et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. Am J Obstet Gynecol 2016;214:424437.CrossRefGoogle ScholarPubMed
Dann, RB, DeLoia, JA, Timms, KM, et al. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. Gynecol Oncol 2012;125:677682.CrossRefGoogle ScholarPubMed
Pennington, KP, Walsh, T, Harrell, MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20:764775.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×